Navigation Links
Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

d of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId re
'"/>




Page: 1 2 3

Related medicine technology :

1. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... -- Trovagene, Inc. (NASDAQ:   TROV), a developer of ... clinical studies will be presented at the 29th International ... for the detection of high risk strains of Human ... place in Seattle from August ... new U.S. patent was issued earlier this year for ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... , , , ... Exposure of Type I Diabetes Patients to Oramed,s Oral,Insulin and of a First-in-Humans Study With ... Oramed Pharmaceuticals, ... of the,American Diabetes Association currently being held in Orlando, Florida . Dr., Miriam Kidron ...
... WASHINGTON , June 28 Harris Corporation (NYSE: ... Inc., is helping to improve the quality of military patient ... Information Exchange (BHIE) interface.  The exchange is a health enterprise ... the Department of Veterans Affairs (VA) to securely share patient ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association 2Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association 3Harris Corporation Leverages CONNECT Solution to Enhance Patient Information Exchange Between DoD and VA 2
(Date:8/20/2014)... -- A group representing U.S. obstetricians is calling for ... According to the American College of Obstetricians and Gynecologists ... the safety and effectiveness of flu vaccination during pregnancy. ... be particularly dangerous to pregnant women, as it can ... Riley, chair of the college,s Immunization Expert Work Group, ...
(Date:8/20/2014)... the immune system is defective in people suffering from irritable ... ongoing issues with pain. , The research the first ... to explain why some painkillers may not offer satisfactory relief ... 10% of the community. There are different forms of ... often has the greatest impact on sufferers, quality of life. ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... and other minor infections might trigger a strong but brief ... study suggests. Just five out of 100,000 children a ... Heather Fullerton, lead author of the study and a professor ... Francisco Benioff Children,s Hospital. "It seems infections play a role ...
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
(Date:8/20/2014)... 20, 2014 With 3943.8% growth, Connexion Point ... the nation’s fastest growing companies. The Inc. 500 ranks Connexion ... sector. Connexion Point is the #1 fastest growing company in ... and Medicaid, and its clients include four of the top ... 1,000 people and has offices and contact centers in Salt ...
Breaking Medicine News(10 mins):Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... M.D., president and CEO of the Regenstrief Institute and ... University School of Medicine, received a 2011 Distinguished Investigator ... Education Meeting on April 28 in Washington, DC. ... and Contribution to Clinical and Translational Science. He is ...
... Australia and Europe. Large resources are set aside for research ... the research field is still new but researchers from ... years ago the Norwegian health care system had a low ... sectors", says Professor Karina Aase at the University of Stavanger. ...
... Injecting a tissue spacer in the prostate-rectal inter-space is ... prostate cancer patients receiving radiation therapy, according to research ... Radiation Therapy Symposium in Atlanta. This symposium is sponsored ... Radiological Society of North America (RSNA)., Even though prostate ...
... 3D models, produced by combining a patient,s CT scans ... planning. 3D printing technology is a fast ... planning. Radiologists are able to transform ultra high-resolution CT ... color printer commonly used in architecture, engineering and construction. ...
... HealthDay Reporter , THURSDAY, April 28 (HealthDay News) -- Men ... risk for developing potentially fatal blood clots, though overall the ... The researchers report that extra weight and extra inches together ... "Tall and obese men had more than a fivefold higher ...
... , THURSDAY, April 28 (HealthDay News) -- Two ... treated have been unanimously recommended for approval by a panel ... Drug Administration advisory committee voted 18-0 that telaprevir, made by ... high rate of rashes that has been reported among those ...
Cached Medicine News:Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:Sustaining vulnerable lives 2Health News:Sustaining vulnerable lives 3Health News:Tissue spacers reduce risk of rectal injury for prostate cancer patients 2Health News:Tall, Obese Men More Prone to Leg Clots: Study 2Health News:New Hepatitis C Drugs Close to Gaining FDA Approval 2Health News:New Hepatitis C Drugs Close to Gaining FDA Approval 3
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: